Abstract: An object of the present invention is to provide an intestinal-environment-improving agent. The object can be achieved by an intestinal-environment-improving agent including an acacia bark extract.
Type:
Application
Filed:
September 30, 2020
Publication date:
November 24, 2022
Applicants:
ACACIA-NO-KI CO., LTD., HOSHI UNIVERSITY
Abstract: The present invention pertains to a medicament for preventing or treating cough, including, as an active ingredient, a compound having P2X4 receptor antagonistic action, a tautomer, stereoisomer, or pharmaceutically acceptable salt of the compound, or a hydrate or solvate thereof.
Type:
Application
Filed:
March 14, 2019
Publication date:
January 7, 2021
Applicants:
NIPPON CHEMIPHAR CO., LTD., HOSHI UNIVERSITY
Abstract: A rhodacyanine derivative represented by the following General Formula (1), wherein, in General Formula (1), R1, R2, and R3 each independently represent an alkyl group which may be substituted; Y1 and Y2 each independently represent a hydrogen atom, a chlorine atom, or a fluorine atom provided that Y1 and Y2 do not represent hydrogen atoms at the same time; and X represents a counter anion. A pharmaceutical composition for treating leishmaniasis including the rhodacyanine derivative and a pharmaceutically acceptable carrier.
Abstract: A wound-dressing material being a product comprising chitosan as a base material and kumazasa extract, and a method for manufacturing the wound-dressing material by gelatinizing a mixture solution containing chitosan and kumazasa extract and drying the resulting gel. The wound-dressing material can be applied to humans and animals, and have biocompatibility, antibacterial effects, and low toxicity, and also have flexibility to be formed into various shapes for applying for various wounds.
Type:
Grant
Filed:
November 14, 2005
Date of Patent:
November 6, 2012
Assignees:
Hoshi Pharmaceutical Co., Ltd., Hoshi University
Abstract: Provided is a medicinal composition, in particular, a medicinal composition for treatment and/or prevention which has a high therapeutic effect on infection with a parasitic protozoa and a selective toxicity thereto and exhibits a life-prolonging effect and so on. A medicinal composition which contains as the active ingredient a benzo[a]phenoxazine compound represented by General formula (1) or a salt compound of the same, in particular, an agent for treating and/or preventing infection with a protozoa such as malaria, leishmaniasis, African trypanosomiasis, Chagas disease, toxoplasmosis, lymphatic filariasis, babesiosis or coccidium disease; and a novel compound which is contained therein as the active ingredient.
Type:
Grant
Filed:
March 11, 2009
Date of Patent:
October 16, 2012
Assignees:
Hoshi University, Synstar Japan Co., Ltd., Swiss Tropical and Public Health Institute, FUJIFILM Corporation
Abstract: A rhodacyanine derivative represented by the following General Formula (1), wherein, in General Formula (1), R1, R2, and R3 each independently represent an alkyl group which may be substituted; Y1 and Y2 each independently represent a hydrogen atom, a chlorine atom, or a fluorine atom provided that Y1 and Y2 do not represent hydrogen atoms at the same time; and X represents a counter anion. A pharmaceutical composition for treating leishmaniasis including the rhodacyanine derivative and a pharmaceutically acceptable carrier.
Abstract: Provided is a medicinal composition, in particular, a medicinal composition for treatment and/or prevention which has a high therapeutic effect on infection with a parasitic protozoa and a selective toxicity thereto and exhibits a life-prolonging effect and so on. A medicinal composition which contains as the active ingredient a benzo[a]phenoxazine compound represented by General formula (1) or a salt compound of the same, in particular, an agent for treating and/or preventing infection with a protozoa such as malaria, leishmaniasis, African trypanosomiasis, Chagas disease, toxoplasmosis, lymphatic filariasis, babesiosis or coccidium disease; and a novel compound which is contained therein as the active ingredient.
Type:
Application
Filed:
March 11, 2009
Publication date:
January 27, 2011
Applicants:
HOSHI UNIVERSITY, SYNSTAR JAPAN CO., LTD., SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE